Stocks · News reference
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Monday, AstraZeneca (NASDAQ:AZN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
While Wall Street analysts maintain a bullish average brokerage recommendation (ABR) of 1.56 for Astrazeneca with 17 Strong Buy ratings, the Zacks Rank system assigns the stock a Strong Sell rating (#5). This contradiction stems from a 10.3% decline in consensus earnings estimates over the past month to $9.16, indicating analyst pessimism about the company's earnings prospects. The article cautions investors against relying solely on brokerage recommendations, which often exhibit positive bias, and suggests the Zacks Rank's focus on earnings estimate revisions is a more reliable predictor of near-term stock performance.
Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.
AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.
Bristol Myers Squibb (BMY) 2-year Phase 3 data shows Sotyktu maintains durable efficacy and safety in active psoriatic arthritis.